| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8819931 | Respiratory Medicine | 2018 | 7 Pages |
Abstract
These results suggest that prednisone therapy aimed at improving or preserving FVC in newly- treated pulmonary sarcoidosis can often be reduced in dose, using a treatment regimen that is characterized by early dose tapering.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Caroline E. Broos, Linda H.C. Poell, Caspar W.N. Looman, Johannes C.C.M. in 't Veen, Marco J.J.H. Grootenboers, Roxane Heller, Leon M. van den Toorn, Monique Wapenaar, Henk C. Hoogsteden, Mirjam Kool, Marlies S. Wijsenbeek, Bernt van den Blink,